Novanta 8-K/A shows Runway Buyer (Riverpoint Medical) FY2025 revenue $136.1M, net income $11.5M

NOVANTA INC

Novanta closed acquisition of Runway Buyer, LLC, parent of Riverpoint Medical, on July 23, 2026 under an Equity Purchase Agreement signed June 8, 2026; deal value not disclosed.
Runway Buyer FY2025 revenue $136.12M, income from operations $33.84M, net income $11.46M; interest expense of $21.11M offset most operating profit.
Dec 31, 2025 balance sheet: total assets $351.69M including goodwill $165.23M and intangibles $93.21M; long-term debt $204.97M; member's equity $116.96M.
FY2025 operating cash flow $27.08M; capex $3.86M; cash $8.19M; debt payments of $22.68M included $11.0M revolver and $11.68M term debt.
Revenue by geography: US $110.57M, Rest of Americas $13.51M, Europe $6.12M, Asia $2.11M; Riverpoint makes surgical fiber, sutures and needles in US and Costa Rica plants.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.